EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS

Consortium Coordinator: Juan José Vaquero (Universidad Carlos III Madrid)

Duration of the action is 72 months (end date Dec 31, 2025)
Number of researchers is >100.

UNIZAR/ARAID
Principal Investigators: Jose A. Aínsa & Santiago Ramón-García
Work Packages 2 (In vitro Profiling) Leaders.
WP2 includes 14 partners and a budget of ca. 20 million euros.

Acrónimo: 
ERA4TB
Autor: 
Ramón García, Santiago
Investigador principal: 
Santiago Ramón Garcia
Organismo gestor: 
Otros
Ámbito: 
Internacional
Entidades participantes: 
UNIVERSIDAD CARLOS III DE MADRID (UC3M)
INSTITUT PASTEUR (IPP)
UNIVERSIDAD DE ZARAGOZA (UNIZAR)
INSTITUT PASTEUR DE LILLE FONDATION (IPL)
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL (SYNAPSE)
FORSCHUNGSZENTRUM BORSTEL (FZB)
FONDATION INNOVATIVE MEDICINES FOR TUBERCULOSIS (IM4TB)
CRITICAL PATH INSTITUTE, LIMITED (C-Path)
CONSIGLIO NAZIONALE DELLE RICERCHE (CNR)
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (CEA)
SERVICIO MADRILENO DE SALUD (SERMAS)
UPPSALA UNIVERSITET (UU)
Department of Health (PHE)
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
KLINIKUM DER UNIVERSITAET ZU KOELN (UHC)
UNIVERSITA DEGLI STUDI DI PADOVA (UNIPD)
UNIVERSITA DEGLI STUDI DI PAVIA (UPV)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)
IMABIOTECH SAS (IBT)
SCIENSANO (SCI)
LATVIJAS ORGANISKAS SINTEZES INSTITUTS (IOS)
BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE (BAR)
QPS NETHERLANDS BV (QPS)
LUNDS UNIVERSITET (LUND)
GRITSYSTEMS AS (GRIT)
GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL (GSK)
EVOTEC INTERNATIONAL GMBH (EVT)
JANSSEN PHARMACEUTICA NV (JANSSEN)
BILL & MELINDA GATES FOUNDATION (BMGF)
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT NON PROFIT ORGANISATION (TBA)
UNIVERSITY OF DUNDEE (UNIVDUN)
Número de investigadores: 
100
Start date: 
01/2020
End date: 
12/2023
Entidad financiadora
Entidad financiadora: 
European Commission H2020
Convocatoria: 
H2020-JTI-IMI2-2018-15-two-stage
Presupuesto
Presupuesto total del proyecto: 
89.815.600€